Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies
Authors:
Open Access
- 12 December 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 39 (1) , 2289007
Abstract
We developed new iminosugar-based glycosidase inhibitors against SARS-CoV-2. Known drugs (miglustat, migalastat, miglitol, and swainsonine) were chosen as lead compounds to develop three classes of glycosidase inhibitors (α-glucosidase, α-galactosidase, and mannosidase). Molecular modelling of the lead compounds, synthesis of the compounds with the highest docking scores, enzyme inhibition tests, and in vitro antiviral assays afforded rationally designed inhibitors. Two highly active α-glucosidase inhibitors were discovered, where one of them is the most potent iminosugar-based anti-SARS-CoV-2 agent to date (EC90 = 1.94 µM in A549-ACE2 cells against Omicron BA.1 strain). However, galactosidase inhibitors did not exhibit antiviral activity, whereas mannosidase inhibitors were both active and cytotoxic. As our iminosugar-based drug candidates act by a host-directed mechanism, they should be more resilient to drug resistance. Moreover, this strategy could be extended to identify potential drug candidates for other viral infections.Keywords
This publication has 84 references indexed in Scilit:
- 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry diseaseBioorganic & Medicinal Chemistry, 2010
- Catalytic Mechanism of Human α-GalactosidaseJournal of Biological Chemistry, 2010
- The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidaseHuman Mutation, 2009
- Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand ComplexesJournal of Medicinal Chemistry, 2006
- Intact α-1,2-endomannosidase is a typical type II membrane proteinGlycobiology, 2005
- Targeting glycosylation as a therapeutic approachNature Reviews Drug Discovery, 2002
- Dry Column Vacuum ChromatographySynthesis, 2001
- 1-N-Iminosugars: Potent and Selective Inhibitors of β-GlycosidasesJournal of the American Chemical Society, 1998
- Endoplasmic Reticulum Glucosidase II Is Composed of a Catalytic Subunit, Conserved from Yeast to Mammals, and a Tightly Bound Noncatalytic HDEL-containing SubunitJournal of Biological Chemistry, 1996
- Synthesis and biological activity of C-6 modified derivatives of the glucosidase inhibitor 1-deoxynojirimycin.Bioorganic & Medicinal Chemistry Letters, 1992